EGFR and neoplasm: Currently, there are a minimum of six fourth‐generation EGFR‐TKIs in early phase I clinical trials, including BLU‐701, BBT‐176, BLU‐945, TRX‐221, BPI‐361175, BDTX‐1535, characterized by their oral bioavailability, mutant selectivity, and thiazole amide structure.[167] BBT‐176 was effective in patients with EGFR‐Ex19Del/T790M/C797S clinically, showing tumor shrinkage and radiological improvements.[168]